Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887016 | 0.90 | SMN1; SMN2 (0.45) | MAPTRXFP1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5886724 | 0.87 | MAPT (0.41) | MAPTRXFP1SMN1; SMN2ALDH1A1HDAC1 | |
| SCHEMBL5886815 | 0.86 | ALDH1A1 (0.40) | MAPTALDH1A1HDAC1 | |
| SCHEMBL5886986 | 0.85 | EPHX2 (0.40) | MAPTALDH1A1MEN1KMT2ARECQL | |
| SCHEMBL5887088 | 0.84 | MET (0.44) | MAPTSMN1; SMN2ALDH1A1MEN1GAA | |
| SCHEMBL5886890 | 0.82 | KLKB1 (0.38) | KMT2ARECQL | |
| SCHEMBL5886951 | 0.82 | SMN1; SMN2 (0.48) | MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5887005 | 0.81 | TSHR (0.47) | MAPTSMN1; SMN2ALDH1A1MEN1GAA | |
| SCHEMBL5886741 | 0.80 | LMNA (0.42) | MAPTSMN1; SMN2ALDH1A1MEN1GAA | |
| SCHEMBL5886765 | 0.79 | MAPT (0.48) | MAPTRXFP1SMN1; SMN2ALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | MAPT 1614/4885RXFP1 4707/4885SMN1; SMN2 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.